Pettinga Financial Advisors LLC reduced its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 75.3% during the second quarter, Holdings Channel.com reports. The firm owned 1,275 shares of the exchange traded fund’s stock after selling 3,886 shares during the quarter. Pettinga Financial Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $202,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Axiom Investment Management LLC bought a new stake in SPDR S&P Biotech ETF during the first quarter valued at about $26,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter worth about $27,000. Financial Life Planners bought a new position in shares of SPDR S&P Biotech ETF in the first quarter worth about $27,000. Intesa Sanpaolo Wealth Management purchased a new position in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $30,000. Finally, SHP Wealth Management purchased a new position in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $31,000.
SPDR S&P Biotech ETF Stock Performance
Shares of NYSEARCA:XBI opened at $157.37 on Monday. The stock has a 50 day moving average of $148.00 and a 200 day moving average of $135.41. The company has a market cap of $10.28 billion, a PE ratio of 11.47 and a beta of 0.83. SPDR S&P Biotech ETF has a 12-month low of $84.81 and a 12-month high of $165.71.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
